I know that it was from the very beginning meant to be an international meeting. So there were people from the region in Asia，but also people from Europe and a few people from the United States as well. In terms of the focus at that time，the major new structural procedure was transcatheter aortic valve replacement. So most of the discussion with respect to the early days of CHINA VALVE（HANGZHOU) had to do with the use of tabby in high risk patients who are not good candidates for surgery.

我记得从会议创始之初就致力于发展成国际化的论坛，所以当时我参会的时候已经有来自亚洲、欧洲和美国的各位专家，当时TAVR处于刚刚发展的阶段，所以在大会上我们主要讨论的是关于高危患者，也就是外科手术不耐受的患者上如何来做TAVR。

We believe that clinical evidence is important to be able to understand the safety and the effectiveness of new therapies and that not every therapy works as intended and patient complications need to be balanced against the potential clinical benefits. Then we have independent committees that look at the evidence and make recommendations that are memorialized in guidelines. And the guidelines require that a certain level of evidence be achieved in order to use and reimburse certain devices.Another important component is that we are at an inflection. where the opportunity to use what we call big data and real-world evidence will provide a new opportunity to see how these devices are performing in clinical practice. 

首先我们开展临床研究，最基本的目标是希望能够了解某一器械或者药物的安全性和有效性。其次，我们希望临床研究能够在应用方面提供更多证据，最终写进指南，指导更多医生高效、安全地使用药物。除此之外，我们还可以用人工智能以及相应的算法来了解某一些器械在真实世界当中的使用情况，包括使用之后的随访数据。

So we strongly support CHINA VALVE（HANGZHOU） as one of the main educational outlets for practitioners and scientists to understand how people practice and how devices are developed in various parts of the world. So we wish all of our colleagues at China Valves，great success，happiness，and a fulfillment with this meeting that allows them to restore some of the friendship relationships to learn many new things that will help them to understand medical concepts and most important to be able to gain insights that will improve patient care in China and in the world.

我们非常支持和赞赏CHINA VALVE（HANGZHOU）在业界所做出的努力，相信大会能够让业界的各位专家了解更多的、更前沿的知识，以及掌握领域内的一些新技术。在此预祝中国杭州瓣膜会取得圆满成功，希望大家在会议上可以建立友谊，有更多的学术交流，最终让中国乃至是世界的患者从中获益。